申请人:SIEMENS HEALTHCARE DIAGNOSTICS INC.
公开号:US10809264B2
公开(公告)日:2020-10-20
A concentrated sample having enhanced concentration of the one or more different populations of target rare molecules is incubated with, for each different population of target rare molecules, a particulate or non-particulate affinity agent that comprises a specific binding partner that is specific for and binds to a target rare molecule. The affinity agent comprises a mass spectrometry (MS) label precursor or a first alteration agent, which either facilitates the formation of an MS label from the MS label precursor or releases an entity that comprises the MS label precursor from the affinity agent. The MS label corresponds to one of the populations of target rare molecules. A second alteration agent is employed if the first alteration agent does not facilitate the formation of an MS label from the MS label precursor. MS analysis is used to determine each different MS label.
针对每种不同的目标稀有分子群,将具有一个或多个不同目标稀有分子群的更高浓度的浓缩样品与微粒或非微粒亲和剂进行孵育,亲和剂包括特异性结合伴侣,该特异性结合伴侣对目标稀有分子具有特异性并能与目标稀有分子结合。亲和剂包括质谱(MS)标签前体或第一改变剂,第一改变剂可促进质谱标签前体形成 MS 标签,或从亲和剂中释放出包含 MS 标签前体的实体。MS 标记与目标稀有分子群之一相对应。如果第一种改变剂不能促进 MS 标签前体形成 MS 标签,则使用第二种改变剂。MS 分析用于确定每个不同的 MS 标签。